Merck prevails in state Fosamax case; United Therapeutics plots N.C. facility expansion;

 @FiercePharma:  Should Big Pharma spin off to goose shares? News |  Follow @FiercePharma

> A jury in state Superior Court in Atlantic City said Fosamax, an osteoporosis medicine made by Merck, did not cause a Pennsylvania woman's jawbone to deteriorate. Article

> United Therapeutics is planning a major expansion of its research-and-manufacturing facility in North Carolina's Research Triangle Park that would allow it to triple its local work force. Report

> KV Pharmaceutical plans to sell nearly 10 million shares at $3.25 each to a group of institutional investors for a total of $32 million. News

> Pfizer has sold more than half of its former Brooklyn, N.Y., complex to a company planning to bring new light-manufacturing and commercial jobs to the long-shuttered site. Item

> Watson Pharmaceuticals' quarterly net income dropped due to legal and acquisition charges, but the generic drugmaker's profit excluding items was in line with analyst expectations. Article

> The Société générale de financement du Québec, a holding company for the provincial government, will proceeed with a $14.7 million equity reinvestment in Axcan Pharma to help fund its $587 million acquisition of Eurand Pharmaceuticals. Report

> Specialty pharmaceutical company Warner Chilcott forecast its 2011 profit range at $3.45 to $3.55 per share, in line with analyst estimates. Story

> Patients using aspirin for heart-attack prevention don't usually need proton pump inhibitors to reduce the risk of bleeding, a new study shows. News

Biotech News

@FierceBiotech: GSK plots new approach to working with academia. Story | Follow @FierceBiotech

@JohnCFierce: BIO: Overall success rates from Phase I to FDA approval is nearly 9%. Item | Follow @JohnCFierce 

> Boston scores R&D coup with Merck KGaA's new hub. Item

> Philogen cancels IPO after Bayer pulls out of cancer deal. News

> Lilly to raise $750M to share R&D costs. Report

> Dealmakers: 2011 should see surge of new M&A pacts. Item 

> Sinclair, IS Pharma in merger talks. News 


Biotech Research News

> Scientists generate lab-dish human heart model. Article 

> Obama pitches $1B boost to NIH funding. Story 

> Mouse-human study IDs celiac disease triggers. Report

> Prostate cancer genome map spotlights DNA damage. News 

> Charles River posts Q4 loss on preclinical writedown. Story

Manufacturing News

> Crucell wins back WHO with plant power fixes. Story 

> Pfizer inherits Wyeth site clean-up. Item 

> FDA zigs to inspect, zags to funds threat. Report

> CMO taps Capsugel for early-phase supply edge. News 

> India considers drug-inspector job requirements. Article 

> Pfizer taps DHL for Australia distribution. Story 

And Finally... The non-profit organization that sets quality and safety standards for drugs approved by FDA is aiming to simplify, clarify and standardize the labels that are affixed to those drugs. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.